BMS and Cipla Settle Litigation Related to Revlimid Patents

shot by IP News Shots / 6:54 pm on 14 December, 2020

Bristol Myers Squibb (BMS) has announced that its subsidiary, Celgene, and Cipla Limited have settled their litigation related to Revlimid patents. As per the settlement, the involved parties shall file Consent Judgments with the US District Court for the District of New Jersey that enjoin Cipla from marketing generic lenalidomide before expiration of the patents-in-suit, except as given in the settlement.

Read more at: https://www.businesswire.com/news/home/20201211005052/en/Bristol-Myers-Squibb-Announces-Settlement-of-U.S.-Patent-Litigation-for-REVLIMID%C2%AE-lenalidomide-with-Cipla

Industry: Pharmaceuticals | Type of IP: Litigations